Who Optimizes SG&A Costs Better? Novartis AG or Iovance Biotherapeutics, Inc.

Optimizing SG&A Costs: A Tale of Two Companies

In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Novartis AG and Iovance Biotherapeutics, Inc. have taken different paths in optimizing these costs. From 2014 to 2023, Novartis AG consistently maintained high SG&A expenses, averaging around $14.5 billion annually. Despite a slight decrease of 16% from 2018 to 2023, their expenses remain substantial. In contrast, Iovance Biotherapeutics, Inc. has seen a dramatic increase in SG&A costs, rising by over 1,000% from 2014 to 2023, reflecting their aggressive growth strategy. This divergence highlights the strategic choices companies make in balancing cost management with growth ambitions. As the industry evolves, these decisions will continue to shape their competitive landscapes.